CRVO
CervoMed Inc.
NASDAQ · Healthcare · Biotechnology · US
$2.43
−4.71%Sep 10, 2026, 11:30 UTC
CervoMed announced that initial results from the Phase 2a clinical trial of neflamapimod in nonfluent variant primary progressive aphasia were accepted as a late-breaking oral session at the ISFTD 2026 annual meeting.
Source:Aug 4, 2026, 09:15 UTC
CervoMed announced that its drug neflamapimod was awarded Innovation Passport designation under the UK Innovative Licensing and Access Pathway for the treatment of dementia with Lewy bodies.
Source:Jul 9, 2026, 11:30 UTC
CervoMed completed enrollment in a Phase 2 study of Neflamapimod for nonfluent variant primary progressive aphasia, a type of frontotemporal dementia.
Source:Jun 22, 2026, 00:00 UTC
CervoMed Inc. signed a securities purchase agreement to issue and sell 2,500,000 shares of common stock at $4.00 per share in a registered direct offering for aggregate gross proceeds of $10.0 million.
Source:Jun 18, 2026, 16:35 UTC
CervoMed Inc. announced a registered direct offering of 2,500,000 shares of common stock at $4.00 per share, expected to close on June 22, 2026.
Source:Jun 18, 2026, 11:00 UTC
CervoMed received a notice of allowance from the USPTO for a new patent protecting the use of neflamapimod in pure dementia with Lewy bodies patients, extending protection into 2042.
Source:Jun 10, 2026, 00:00 UTC
CervoMed Inc. completed a private placement financing raising approximately $10.5 million in gross proceeds through the sale of units consisting of common stock, pre-funded warrants, Series B warrants, and Series C warrants.
Source: